Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Remon

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Cancer Treatment Reviews|April 9, 2016
Thymic malignancies: Moving forward with new systemic treatmentsJ Remon, C R Lindsay, M V Bluthgen, et al.
Cancer Treatment Reviews|October 26, 2018
Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?J Remon, L E Hendriks, C Cabrera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Are liquid biopsies a surrogate for tissue EGFR testing?J W Goldman, Z S Noor, J Remon, et al.
Cancer Treatment Reviews|April 25, 2014
Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcomeJ Remon, T Morán, N Reguart, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 23, 2015
miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancersJ Remon, D Alvarez-Berdugo, M Majem, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experienceM V Bluthgen, C Boutros, F Fayard, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 20, 2020
Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicineJ Remon, F Tabbò, B Jimenez, et al.
Revue Des Maladies Respiratoires|May 22, 2021
[NSCLC and new oncogenic mutations: Diagnosis and perspectives]C Basse, A Swalduz, A Mc Leer, et al.
Cancer Treatment Reviews|July 9, 2013
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era beginsJ Remon, T Morán, M Majem, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|March 29, 2014
Acute drop in blood monocyte count differentiates NEC from other causes of feeding intoleranceJ Remon, R Kampanatkosol, R R Kaul, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Cancer Treatment Reviews|April 9, 2016
Thymic malignancies: Moving forward with new systemic treatmentsJ Remon, C R Lindsay, M V Bluthgen, et al.
Cancer Treatment Reviews|October 26, 2018
Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?J Remon, L E Hendriks, C Cabrera, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2018
Are liquid biopsies a surrogate for tissue EGFR testing?J W Goldman, Z S Noor, J Remon, et al.
Cancer Treatment Reviews|April 25, 2014
Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcomeJ Remon, T Morán, N Reguart, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 23, 2015
miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancersJ Remon, D Alvarez-Berdugo, M Majem, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experienceM V Bluthgen, C Boutros, F Fayard, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 20, 2020
Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicineJ Remon, F Tabbò, B Jimenez, et al.
Revue Des Maladies Respiratoires|May 22, 2021
[NSCLC and new oncogenic mutations: Diagnosis and perspectives]C Basse, A Swalduz, A Mc Leer, et al.
Cancer Treatment Reviews|July 9, 2013
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era beginsJ Remon, T Morán, M Majem, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|March 29, 2014
Acute drop in blood monocyte count differentiates NEC from other causes of feeding intoleranceJ Remon, R Kampanatkosol, R R Kaul, et al.
Pageof 6